RBCC Seeks Out New Opportunities North of the Border

RBCC Seeks Out New Opportunities North of the Border

NOKOMIS, Fla.--(BUSINESS WIRE)-- As Rainbow Coral Corp. (OTCBB: RBCC) continues its aggressive push into the $232 billion personalized medicine market, the company is seeking out promising opportunities in a new, potentially lucrative territory: Canada.

"In spite of its world-class healthcare system, Canada remains a highly underdeveloped market for personalized medicine products, services and innovations," said RBCC CEO Patrick Brown. "Our research indicates that some forward-thinking investment there could lead to big returns for our company as we work to deliver new cutting-edge tools for the future of global medicine."

In the U.S., RBCC is already hard at work achieving its goals. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. RBCC's joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.

Canada could represent the perfect opportunity to expand on the company's biotech initiatives.

"It's a wide-open market with unlimited potential for growth," Brown said.

For more information on RBCC's biotechnology projects, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com

KEYWORDS: United States North America Canada Florida

INDUSTRY KEYWORDS:

The article RBCC Seeks Out New Opportunities North of the Border originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.